GEN Exclusives

More »

GEN News Highlights

More »
May 26, 2010

Pozen Gets $20M from AstraZeneca after U.S. Approval of Vimovo

  • Pozen confirmed receipt of a $20 million milestone payment from AstraZeneca following FDA’s recent approval of Vimovo™ delayed-release tablets for relieving the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and for decreasing the risk of NSAID-related gastric ulcers in high-risk patients. Pozen says it will transfer ownership of the Vimovo IND application and NDA to AstraZeneca over the next few weeks.

    An additional $25 million milestone will be payable to Pozen if the drug receives marketing approval as well as pricing and reimbursement approval in a major non-U.S. market. The firm notes that AstraZeneca submitted an MAA to the European Medicines Association for Vimovo in October 2009. Pozen could in addition receive up to $260 million in sales performance milestones.

    Pozen and AstraZeneca signed their global collaboration for Vimovo in August 2006. Under the terms of the agreement, Pozen received an upfront fee of $40 million and was eligible for potential aggregate development and regulatory milestone payments of $160 million. Pozen retained responsibility for the development and regulatory clearance of the drug in the U.S., with AstraZeneca taking on all non-U.S. development and regulatory activities for the drug as well as all aspects of manufacturing, marketing, sales, and distribution worldwide.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?